SEARCH

SEARCH BY CITATION

References

  • 1
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 55662.
  • 2
    World Health Organization. Fact Sheet No. 164. Hepatitis C. Geneva: World Health Organization, 2000.
  • 3
    Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003; 23 (Suppl. 1): 3546.
  • 4
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 5
    Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterol Clin North Am 2004; 33: S2535.
  • 6
    Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 162332.
  • 7
    Devine EB, Kowdley KV, Veenstra DL, Sullivan SD. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications. Value Health 2001; 4: 37684.
  • 8
    Gaeta GB, Precone DF, Felaco FM, et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ’real world’ patients with chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 16339.
  • 9
    Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 34655.
  • 10
    Iwasaki Y, Araki Y, Ikeda H, et al. Predictive factors for dose modification and premature discontinuation of interferon plus ribavirin for adverse effects in Japanese patients with chronic hepatitis C. Gastroenterology 2003; 124 (4 Suppl. 1): P203 (Abstract).
  • 11
    Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 95865.
  • 12
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 (Suppl. 1): 6775.
  • 13
    Weisz K, Kreiswirth S, McMeeking M, et al. and the Hepatitis Resource Network. Erythropoietin use for ribavirin/interferon induced anemia in patients with hepatitis C. Hepatology 1998; 28: 288A (Abstract).
  • 14
    Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S23744.
  • 15
    Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 130211.
  • 16
    Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005; 39: S913.
  • 17
    Dieterich DT, Spivak JL. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003; 37: 53341.
  • 18
    National Institutes of Health. Management of Hepatitis C: 2002. NIH Consensus and State-of-the-Science Statements, Vol. 19. National Institutes of Health, 2002: 146.
  • 19
    Wright TL, Yee H. VA treatment recommendations (Version 5.0). Patients with chronic hepatitis C. Fed Pract 2003; 20 (Suppl. 5): 133.
  • 20
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 114771.
  • 21
    Dieterich DT, Pockros P, Schiff E, et al. Epoetin alfa (PROCRIT) once weekly maintains ribavirin dose in hepatitis C virus (HCV)-infected patients treated with combination therapy: interim results of a randomized, double-blind, placebo-controlled study. Hepatology 2002; 36 (4 Part 2): 286A (Abstract).
  • 22
    Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24919.
  • 23
    Gergely AE, Lafarge P, Fouchard-Hubert I, Lunel-Fabiani F. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Hepatology 2002; 35: 12812.
  • 24
    Sood A, Reddy N, Russo M, Brown R, Jacobson I. Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection. Hepatology 2001; 34 (4 Part 2): 429A (Abstract).
  • 25
    Pockros PJ, Shiffman ML, Schiff ER, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40: 14508.
  • 26
    Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000; 32: 64753.
  • 27
    McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 148592.
  • 28
    Ferenci P, Austria W, Shiffman M, et al. Early prediction of response to 40 KDA peginterferon alfa-2A (Pegasys) plus ribavirin (RBV) in patients with chronic hepatitis C (CHC). Hepatology 2001; 34 (4 Part 2): 351A (Abstract).
  • 29
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 64552.
  • 30
    McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10619.
  • 31
    Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 32
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 47381.
  • 33
    Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 101523.
  • 34
    Shiffman ML. Retreatment of HCV non-responders with peginterferon and ribavirin: results from the lead-in phase of the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) trial. Hepatology 2002; 36 (4 Part 2): 295A (Abstract).
  • 35
    Shiffman M, Price A, Hubbard S, et al. Treatment of chronic Hepatitis C virus (HCV) genotype 1 with peginteferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and Epoentin alfa (EFO) enhances sustained virologic response (SVR). Hepatology 2005; 42: 217A.
  • 36
    Schrag D. The price tag on progress – chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 3179.
  • 37
    Inadonmi J. Decision analysis and economic modelling: a primer. Eur J Gastroenterol Hepatol 2004; 16: 53542.
  • 38
    PDR Staff 2004. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson PDR, 2004.
  • 39
    Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 22837.
  • 40
    Afdhal N, Dieterich D, Pockros P, et al. Epoetin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels, and improves quality of life vs placebo: a randomized, double-blind, multicenter study. Gastroenterology 2003; 124 (4 Suppl. 1): A-714 (Abstract).
  • 41
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 131824.
  • 42
    Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
  • 43
    Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 42532.
  • 44
    Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. CMAJ 1993; 148: 9279.
  • 45
    Ubel P, Hirth R, Chernew M, Fendrick A. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2005; 163: 163741.
  • 46
    Spiegel BMR, Chen K, Chiou CF, Robbins S, Younossi ZR. Erythropoietic growth factors for treatment-induced anemia in hepatitis C: a cost-effectiveness analysis. Clin Gastroenterol Hepatol 2005; 3: 103442.
  • 47
    Foster GR. Past, present, and future hepatitis C treatments. Semin Liver Dis 2004; 24 (Suppl. 2): 97104.
  • 48
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 226571.
  • 49
    Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002; 36: 12739.
  • 50
    Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 14038.
  • 51
    Bunn HF. Drug-induced autoimmune red-cell aplasia. N Engl J Med 2002; 346: 5223.
  • 52
    Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 46975.
  • 53
    Lorber C, Willfort A, Ohler L, et al. Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia. Ann Hematol 1993; 67: 136.